featured
Low-Dose vs Standard-Dose Olanzapine With Triple Antiemetic Therapy for Preventing Nausea and Vomiting in Patients With Solid Tumours After Highly Emetogenic Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
Lancet Oncol 2024 Feb 01;25(2)246-254, J Bajpai, V Kapu, S Rath, S Kumar, A Sekar, P Patil, A Siddiqui, S Anne, A Pawar, S Srinivas, P Bhargava, S Gulia, V Noronha, A Joshi, K Prabhash, S Banavali, R Sarin, R Badwe, S GuptaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.